TumCI Cancer Research Results

TumCI, Tumor Cell invasion: Click to Expand ⟱
Source:
Type:
Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms:

1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion.

2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue.

3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment.

4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream.

5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body.

6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection.

7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs.

8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis.
Scientific Papers found: Click to Expand⟱
8348- Lut,    Lutein inhibits proliferation, invasion and migration of hypoxic breast cancer cells via downregulation of HES1
- in-vitro, BC, MCF7 - in-vitro, BC, MDA‑MB‑157
TumCP↓, Apoptosis↑, Hif1a↓, NOTCH↓, HES1↓, EMT↓, TumCI↓, TumCMig↓, ROS↓,
8343- Lut,    Association of Lutein with Cancer: A Systematic Review of the Lutein Effects on Cellular Processes Involved in Cancer Progression
- Review, Var, NA
*antiOx↑, *Inflam↓, Risk↓, AntiCan∅, Apoptosis↑, ROS↓, NRF2↓, Akt↓, ERK↓, NF-kB↓, Bcl-2↓, BAX↑, Casp3↑, DNAdam↑, ROS↓, P53↑, PCNA↓, cycD1/CCND1↓, TumCP↓, Hif1a↓, NOTCH↓, miR-590-3p↑, TumCMig↓, TumCI↓, TumMeta↓, TumCA↓, *BioAv↓,
3262- Lyco,    Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1
- in-vitro, adrenal, SK-HEP-1
TumCI↓, MMP9↓, NF-kB↓, Sp1/3/4↓, IGF-1R↓, i-ROS↓,
3275- Lyco,    Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer
- Review, Var, NA
TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, P21↑, P53↑, GSK‐3β↓, p27/CDKN1B↓, Akt↓, mTOR↓, ROS↓, MMPs↓, TumCI↓, TumCMig↓, NF-kB↓, *iNOS↓, *COX2/PTGS2↓, lipid-P↓, GSH↑, NRF2↑,
1126- Lyco,    Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway
- vitro+vivo, Oral, NA
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EMT↓, PI3K↓, Akt↓, mTOR↓, E-cadherin↓, BAX↑, N-cadherin↓, p‑PI3K↓, p‑Akt↓, p‑mTOR↓, Bcl-2↓,
4782- Lyco,    New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, TumCI↓, TumCA↓, ROS↓, MMP2↓, MMP7↓, MMP9↓, VEGF↓, E-cadherin↑, TIMP1↑, TIMP2↑, BioAv↝, *IL12↓, *TNF-α↓, *IL1↓, *IL1β↓, *IL6↓, COX2/PTGS2↓, iNOS↓, *radioP↑, NF-kB↓, survivin↓, Casp3↑, Bax:Bcl2↑,
4791- Lyco,    Investigating into anti-cancer potential of lycopene: Molecular targets
- Review, Var, NA
*antiOx↑, TumCP↓, TumCCA↓, Apoptosis↑, TumCI↓, angioG↓, TumMeta↓, *Risk↓, cycD1/CCND1↓, CycD3↓, cycE/CCNE↓, CDK2↓, CDK4↓, Bcl-2↓, P21↑, p27/CDKN1B↑, P53↑, BAX↑, selectivity↑, MMP↓, Cyt‑c↑, Wnt↓, Synergy↑, PPARγ↑, LDL↓, Akt↓, PI3K↓, mTOR↓, PDGF↓, NF-kB↓, ChemoSen↑,
8520- MAG,    The natural compound magnolol inhibits invasion and exhibits potential in human breast cancer therapy
- in-vitro, BC, MDA-MB-231
TumCI↓, MMP9↓, NF-kB↓, *toxicity↓,
8518- MAG,    Magnolol suppresses the proliferation and invasion of cholangiocarcinoma cells via inhibiting the NF-κB signaling pathway
- in-vitro, CCA, NA
TumCG↓, TumCMig↓, TumCI↓, PCNA↓, Ki-67↓, MMP2↓, MMP7↓, MMP9↓, TumCCA↑, cycD1/CCND1↓, p‑IκB↓, p‑p65↓, NF-kB↓,
8498- MAG,    Induction of apoptosis by magnolol via the mitochondrial pathway and cell cycle arrest in renal carcinoma cells
- in-vitro, Kidney, 786-O - in-vitro, RCC, OS-RC-2 - in-vitro, Nor, HK-2
Apoptosis↑, TumCCA↑, selectivity↑, TumCMig↓, TumCI↓, MPT↑, ROS↓, MMP↓, mtDam↑,
8499- MAG,    Wnt/β-catenin signaling mediates the antitumor activity of magnolol in colorectal cancer cells
- vitro+vivo, CRC, SW480 - in-vitro, CRC, HCT116
β-catenin/ZEB1↓, TCF↓, TOPflash↓, cMyc↓, MMP7↓, UroPA↓, TumCI↓,
8505- MAG,    Role of magnolol in gastrointestinal cancers: Recent trends and future perspectives
- Review, GC, NA
TumCP↓, TumCI↓, TumCMig↓, angioG↓, EMT↓, TumCCA↑, Apoptosis↑, PI3K↝, Akt↝, NF-kB↝, MAPK↝, JNK↝, ERK↝, TGF-β↝, Smad1↝,
8511- MAG,    Suppression of PKCδ/NF-κB Signaling and Apoptosis Induction through Extrinsic/Intrinsic Pathways Are Associated Magnolol-Inhibited Tumor Progression in Colorectal Cancer In Vitro and In Vivo
- vitro+vivo, CRC, HT-29 - in-vitro, Colon, CT26
p‑PKCδ↓, p‑NF-kB↓, TumCI↓, Fas↓, FasL↓, TumCG?, toxicity↓, cl‑Casp8↑, MMP↓, Casp9↑, ChemoSen↑,
4528- MAG,    Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update
- Review, Nor, NA
*Inflam↑, *cardioP↑, *angioG↓, *antiOx↑, *neuroP↑, *Bacteria↓, AntiTum↑, TumCG↓, TumCMig↓, TumCI↓, Apoptosis↑, E-cadherin↑, NF-kB↓, TumCCA↑, cycD1/CCND1↓, PCNA↓, Ki-67↓, MMP2↓, MMP7↓, MMP9↓, TumCG↓, Casp3↑, NF-kB↓, Akt↓, mTOR↓, LDH↓, Ca+2↑, Synergy↑, *toxicity↓, *BioAv↝, *PGE2↓, *TLR2↓, *TLR4↓, *MAPK↓, *PPARγ↓,
4535- MAG,  5-FU,    Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways
- in-vitro, Cerv, NA
ChemoSen↑, TumCP↓, vinculin↓, TumCA↓, TumCMig↓, TumCI↓, p‑Akt↓, p‑PI3K↓, mTOR↓, E-cadherin↑, β-catenin/ZEB1↑, Snail↓, Slug↓,
4531- MAG,    Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway
- in-vitro, CRC, HCT116
Apoptosis↑, DNAdam↑, Casp3↑, cl‑PARP↑, p‑AMPK↑, Bcl-2↓, P53↑, BAX↑, Cyt‑c↑, TumCMig↓, TumCI↓,
4520- MAG,    Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
- vitro+vivo, PC, PANC1
Vim↓, E-cadherin↑, EMT↓, N-cadherin↓, p‑SMAD2↓, p‑SMAD3↓, TumCP↓, TumCMig↓, TumCI↓, TGF-β↓,
1196- MAG,    2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression
- in-vitro, HCC, NA
TumCG↓, TumCMig↓, TumCI↓, TumCCA↑, HDAC↓,
5252- MAG,    Insights on the Multifunctional Activities of Magnolol
- Review, Var, NA
BioAv↓, *Inflam↓, *Bacteria↓, *antiOx↑, *neuroP↑, *cardioP↑, CYP1A1↓, *PPARγ↑, *NF-kB↓, *COX2/PTGS2↓, *iNOS↓, *ROS↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, P21↑, TumCG↓, TumCMig↓, TumCI↓, Ki-67↓, PCNA↓, MMP2↓, MMP9↓, MMP7↓, DNAdam↑, MMP↓, TumCP↓, selectivity↑, PI3K↓, Akt↓, H2O2↓, Hif1a↓, *BDNF↑, *NRF2↑, *AChE↑,
8566- Matr,    Matrine suppresses lung metastasis of human hepatocellular carcinoma by directly targeting matrix metalloproteinase-9
- vitro+vivo, HCC, MHCC-97H
TumCMig↓, TumCI↓, Dose↓, MMP9↓, TumMeta↓,
8569- Matr,    Matrine inhibits the metastatic properties of human cervical cancer cells via downregulating the p38 signaling pathway
- vitro+vivo, Cerv, NA
TumCG↓, Apoptosis↑, TumCI↓, TumCMig↓, MMP2↓, MMP9↓, p38↓, TumCG↓, TumMeta↓,
8570- Matr,    Matrine suppresses invasion of castration-resistant prostate cancer cells by downregulating MMP-2/9 via NF-κB signaling pathway
- vitro+vivo, Pca, DU145 - in-vitro, Pca, PC3
TumCG↓, TumCMig↓, TumCI↓, MMP9↓, MMP2↓, p‑p65↓, NF-kB↓,
8576- Matr,    Matrine reduces the proliferation and invasion of colorectal cancer cells via reducing the activity of p38 signaling pathway
- vitro+vivo, CRC, NA
TumCMig↓, TumCI↓, MMP2↓, MMP9↓, p‑p38↓, TumMeta↓,
8542- Matr,    Matrine Suppresses Lung Cancer Progression via Dual Inhibition of CHEK1-Mediated DNA Damage Repair and PI3K/AKT Survival Signaling
- vitro+vivo, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, TumCCA↑, p‑PI3K↓, CHK1↓, p‑Akt↓, Bcl-2↓, MTA1↓, Vim↓, MMP2↓, MMP9↓, γH2AX↑, E-cadherin↑, BAX↑, cl‑Casp3↑, Ki-67↓, TumCG↓,
8538- Matr,    Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling
- in-vitro, BC, MDA-MB-231 - ex-vivo, BC, MDA-MB-231
TumCP↓, Synergy↑, Apoptosis?, Bax:Bcl2↑, TumCI↓, MMP9↓, MMP2↓, Akt↓, NF-kB↓, VEGFR1↓, BioAv↝,
8537- Matr,    Matrine restrains the development of colorectal cancer through regulating the AGRN/Wnt/β-catenin pathway
- vitro+vivo, CRC, NA
TumCG↓, AGRN↓, TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, Wnt↓, β-catenin/ZEB1↓,
8530- Matr,    Matrine inhibits the invasive and migratory properties of human hepatocellular carcinoma by regulating epithelial‑mesenchymal transition
- in-vitro, HCC, NA
TumCP↓, TumCMig↓, TumCI↓, E-cadherin↑, Vim↓, MMP2↓, MMP9↓, Snail↓, Slug↓, EMT↓, PIP3↑, PTEN↑, p‑Akt↓,
8544- Matr,    Matrine in Liver Diseases: Mechanistic Insights and Therapeutic Potential
- Review, BC, NA
*hepatoP↑, *Inflam↓, *ROS↓, *ER Stress↓, *lipid-P↓, TumCP↓, TumCI↓, TumCMig↓, TumAuto↑, Apoptosis↑, *AST↓, *ALAT↓, *SOD↑, *MDA↓, *TNF-α↓, *IL6↓, *NRF2↑, *HO-1?, *NF-kB↓, *Inflam↓, AFP?, PCNA↓, cMyc↓, Bcl-2↓, BAX↑, EMT↓, MDM2↓, P53↑, PI3K↓, Akt↓, mTOR↓, Beclin-1/ATG6↑, NOTCH↑, ChemoSen↑, eff↑, survivin↓, XIAP↓, Synergy↑,
8555- Matr,    Matrine Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review
- Review, Var, NA
*AntiTum↑, *Inflam↓, *Analgesic↑, *AntiViral↑, *Imm↑, *PI3K↑, *Akt↑, *mTOR↑, TumAuto↑, PI3K↓, Akt↓, mTOR↓, Beclin-1/ATG6↑, E-cadherin↑, Vim↓, MMP2↓, MMP9↓, Snail↓, Slug↓, PTEN↑, TumCP↓, TumCMig↓, TumCI↓, ChemoSen↑, ROS↑, uPA↓, p‑ERK↓, cachexia↓, antiD↑, GSK‐3β↓, LC3B-II↑, p62↓, Apoptosis↑, Casp3↑, Casp8↑, Casp9↑, FOXO1↑, FOXO3↑, FOXO4↑, PARP↑, BIM↑, Bcl-2↓, survivin↓, miR-21↓, *HOTAIR↑, *p‑Akt↑, *p‑STAT3↑, *STAT3↑, *ROS↓, Wnt↓, β-catenin/ZEB1↓, NOTCH1↓, JAG1↓, HES1↓, BioAv↝, toxicity↝,
8553- Matr,    Research progress on the pharmacological effects of matrine
- Review, Nor, NA
*AntiCan↑, *antiAll↑, *Stroke↓, TumCI↓, TumCMig↓, TumCP↓, TumCCA↑, *AGEs↓, *Inflam↓, *antiOx↑, *neuroP↑, *Apoptosis↓, *IBI↑, *GutMicro↑, EGFR↓, *HSP60/HSPD1↓, *antiOx↑, *GSH↑, *Catalase↑, *AChE↓, *BChE↓, *neuroP↑, *PI3K↑, *Akt↑, *mTOR↑, *cognitive↑, *ROS↓, *toxicity↑,
8550- Matr,    Matrine improves the hepatic microenvironment and reverses epithelial-mesenchymal transition in hepatocellular carcinoma by inhibiting the Wnt-1/β-catenin signaling pathway
- vitro+vivo, Liver, HUH7
other↝, Wnt↓, β-catenin/ZEB1↓, EMT↓, TumCMig↓, TumCI↓, Inflam↓, hepatoP↑, AST?, ALB↑, ALAT↓, ALP↓, GGT/CD224↓, TBIL↓, DBIL↓, IBIL↓,
8547- Matr,    Matrine in cancer therapy: antitumor mechanisms and nano-delivery strategies
- Review, Var, NA
*Ingr↝, *AntiTum↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, TumCP↓, TumCMig↓, TumCI↓, JPT1/HN1↓, Erlin1↑, LINC01116↓, miR-592↑, ERK↓, JAK↓, STAT3↓, miR-182-5p↓, PI3K↓, Akt↓, Wnt↓, β-catenin/ZEB1↓, Sharpin↓, ROS↓, AMPK↑, mTOR↓, Snail↓, Vim↓, N-cadherin↓, MMP2↓, MMP9↓, E-cadherin↑, PTEN↑, miR-10b-5p↓, GPx4↓, lipid-P↑, Iron↑, Piezo1↑,
8639- MBZ,    Repurposing mebendazole to reprogram oncogenic and tumor-suppressor networks: Multi-cancer insights from ENOX2, MMP2, RASSF1A, WFDC10A and METTL7A
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vitro, Liver, HepG2 - in-vitro, AML, K562
ENOX2↓, MMP2↓, TumCI↓, RASSF1A↑, WFDC10A↑, METTL7A↑,
8821- MCP,  Rad,    Modified Citrus Pectin as a Potential Sensitizer for Radiotherapy in Prostate Cancer
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145
Gal-3↓, TumCP↓, angioG↓, Apoptosis↑, RadioS?, BAX↓, DNArepair↓, PCNA↓, TumCI↓, TumCCA↑, ROS↑,
8819- MCP,  PacT,    Pectasol‐C Modified Citrus Pectin targets Galectin‐3‐induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids
- in-vitro, Ovarian, SKOV3
Gal-3↓, ChemoSen↑, STAT3↓, Hif1a↓, Akt↓, TumCMig↓, TumCI↓, ITGA2↓, ITGA5↓, ITGA6↓, ITGB1↓, ITGB3↓, ITGB4↓,
8716- MeJa,    Methyl jasmonate abolishes the migration, invasion and angiogenesis of gastric cancer cells through down-regulation of matrix metalloproteinase 14
- in-vitro, GC, SGC-7901 - in-vitro, GC, MKN-28
TumCMig↓, TumCI↓, angioG↓, MMP14↓, VEGF↓, Sp1/3/4↓,
8761- MeSA,    Methylseleninic Acid Suppresses Breast Cancer Growth via the JAK2/STAT3 Pathway
- in-vitro, BC, 4T1
TumCI↓, Apoptosis↑, Casp3↑, PARP1↑, BAX↑, JAK2↓, STAT3↓,
6538- MeSal,  ASA,    Salicylate induces AMPK and inhibits c-MYC to activate a NRF2/ARE/miR-34a/b/c cascade resulting in suppression of colorectal cancer metastasis
- in-vitro, CRC, NA
chemoPv↑, AMPK↑, NRF2↑, miR-34a↑, cMyc↓, tumCV↓, Apoptosis↑, TumCI↓, TumCMig↓, MET↑,
2384- MET,    Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication
- in-vitro, Thyroid, BCPAP - in-vivo, NA, NA - in-vitro, Thyroid, TPC-1
Glycolysis↓, OXPHOS↑, tumCV↓, TumCI↓, TumCMig↓, EMT↓, Apoptosis↑, TumCCA↑, LDHA↓, PKM2↓, IDH1↑, TumCG↓,
2378- MET,    Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway
- in-vitro, SCC, CAL27 - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,
2375- MET,    Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling
- in-vitro, GC, SGC-7901
tumCV↓, TumCI↓, TumCMig↓, Apoptosis↑, PARP↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, COX2/PTGS2↓,
2387- MET,  GEM,    Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis
- in-vitro, CCA, HCC9810
Synergy↑, tumCV↓, TumCMig↓, TumCI↓, Apoptosis↑, PKM2↓, PDHB↓,
970- MET,    Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer
- in-vitro, BC, NA
CAFs/TAFs↝, p‑AMPK↑, PHDs↑, Hif1a↓, TumCI↓,
5247- MF,    Anticancer Activity by Magnetic Fields: Inhibition of Metastatic Spread and Growth in a Breast Cancer Model
- in-vivo, BC, MDA-MB-468
TumCI↓,
3470- MF,    Pulsed electromagnetic fields inhibit IL-37 to alleviate CD8+ T cell dysfunction and suppress cervical cancer progression
- in-vitro, Cerv, HeLa
TNF-α↑, IL6↑, ROS↑, Apoptosis↑, TumCP↓, TumCMig↓, TumCI↓,
3500- MF,    Moderate Static Magnet Fields Suppress Ovarian Cancer Metastasis via ROS-Mediated Oxidative Stress
- in-vitro, Ovarian, SKOV3
ROS↑, CSCs↓, CD44↓, SOX2↓, cMyc↓, TumMeta↓, TumCI↓, TumCMig↓, CD133↓, Nanog↓,
3478- MF,    One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study
- Trial, BC, NA - in-vitro, BC, MCF7 - in-vitro, Nor, C2C12
TumCP↓, TumCMig↓, TumCI↓, *toxicity∅, TGF-β↓, Twist↓, Slug↓, β-catenin/ZEB1↓, Vim↓, p‑SMAD2↓, p‑SMAD3↓, angioG↓, VEGF↓, selectivity↑, LIF↑,
4354- MF,  doxoR,    Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach
- in-vivo, BC, MDA-MB-231 - in-vivo, BC, MCF7
selectivity↑, Apoptosis↑, TumCI↓, tumCV↓, TumVol↓, eff↓, ChemoSen↑, ROS↑, Ca+2↑, TumCMig↓,
5242- MFrot,    Rotating magnetic field downregulating type XI collagen to suppress triple-negative breast cancer metastasis by inactivating the ITGB1/FAK/YAP signaling pathway
- in-vitro, BC, NA
TumCI↓, COL11A1↓, TumCG↓, TumMeta↓, ITGB1↓, FAK↓, YAP/TEAD↓, Dose↝,
205- MFrot,  MF,    Intermittent F-actin Perturbations by Magnetic Fields Inhibit Breast Cancer Metastasis
- vitro+vivo, BC, MDA-MB-231
OS↑, F-actin↓, TumCI↓, TumCMig↓, Rho↓, selectivity↑, TumMeta↓,

Showing Research Papers: 351 to 400 of 546
Prev Page 8 of 11 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 546

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↑, 1,   NA?, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

4-HNE↑, 1,   antiOx↓, 2,   antiOx↑, 6,   ARE↓, 1,   Catalase↓, 3,   Copper↑, 1,   ENOX2↓, 1,   Fenton↑, 2,   GPx↓, 1,   GPx↑, 2,   GPx1↓, 1,   GPx4↓, 13,   GSH↓, 27,   GSH↑, 2,   GSR↓, 1,   GSTs↑, 1,   H2O2↓, 2,   H2O2↑, 2,   HO-1↓, 5,   HO-1↑, 9,   Iron↑, 4,   i-Iron↑, 1,   Keap1↓, 1,   Keap1↑, 1,   lipid-P?, 1,   lipid-P↓, 3,   lipid-P↑, 8,   MDA?, 1,   MDA↑, 7,   i-MDA↑, 1,   NADH↓, 2,   NQO1?, 1,   NQO1↑, 1,   NRF2↓, 16,   NRF2↑, 15,   Prx↓, 1,   Prx4↑, 1,   PrxII↓, 1,   PYCR1↓, 1,   ROS↓, 19,   ROS↑, 146,   ROS⇅, 2,   ROS↝, 2,   ROS∅, 1,   i-ROS↓, 1,   i-ROS↑, 1,   mt-ROS↑, 5,   SOD↓, 5,   SOD↑, 2,   SOD1↓, 1,   SOD1↑, 1,   SOD2↓, 4,   SOD2↑, 1,   TAC↓, 1,   TAC↑, 1,   TKT↝, 1,   Trx↓, 2,   ox-Trx1↑, 1,   TrxR↓, 5,   TrxR1↓, 3,   xCT/SLC7A11↓, 5,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↓, 1,   IronCh∅, 1,   Tf↓, 1,   Tf↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

BCR-ABL↓, 1,   CDC2↓, 4,   CDC25↓, 6,   compI↓, 1,   compIII↓, 1,   compV↓, 1,   compV↓, 1,   EGF↓, 1,   ETC↓, 3,   MFN2↓, 1,   mitResp↑, 1,   Mortalin↓, 1,   mtDam↑, 14,   OCR↓, 6,   OCR↑, 1,   OXPHOS↓, 2,   OXPHOS↑, 5,   mt-OXPHOS↓, 1,   PDH↑, 2,   PDH↝, 1,   PDH∅, 1,   PGC-1α↑, 1,   PINK1↑, 3,   SIRT3↑, 2,   VDAC1↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 2,   5LO↓, 3,   ACADS/SCAD↓, 1,   ACC↓, 2,   ACLY↓, 1,   ACSL4↑, 1,   ALAT↓, 2,   AMPK↓, 1,   AMPK↑, 25,   AMPK↝, 1,   p‑AMPK↑, 5,   ATP↓, 19,   CAIX/CA9↓, 1,   citrate↓, 1,   ECAR↓, 3,   ENO1↓, 1,   FABP4↑, 1,   FABP5/E-FABP↓, 1,   FAM↓, 1,   FASN↓, 6,   FDG↓, 1,   G6PD↓, 5,   GAPDH↓, 2,   GLS↓, 1,   glucoNG↓, 1,   GlucoseCon↓, 11,   GlutMet↓, 1,   Glycolysis↓, 34,   GSK‐3β↓, 10,   GSK‐3β↑, 1,   GSK‐3β↝, 1,   p‑GSK‐3β↓, 1,   Histones↑, 1,   ac‑Histones↑, 1,   HK1↓, 1,   HK2↓, 17,   HMG-CoA↓, 1,   IDH1↑, 1,   lactateProd↓, 11,   lactateProd↑, 1,   LDHA↓, 11,   LDHA∅, 1,   LDL↓, 3,   lipidLev↓, 2,   lipoGen↓, 2,   NADPH↓, 1,   PDHB↓, 1,   PDK1 / PDPK1↓, 5,   p‑PDK1 / PDPK1↓, 1,   PFK↓, 4,   PFK1↓, 1,   PGK1↓, 2,   PGM1↓, 1,   PIP3↑, 1,   PKM2↓, 19,   PKM2∅, 1,   Pyruv↓, 1,   R5P↝, 1,   RARα↓, 1,   RARβ↑, 1,   RARγ↑, 1,   p‑S6↓, 1,   SCD1↓, 2,   SIRT1↓, 5,   SIRT1↑, 4,   SIRT2↑, 1,   SREBP1/SREBF1↓, 3,   SREBP2↓, 2,   TCA↓, 1,   Warburg↓, 8,  

Cell Death(tgid=5) ⓘ

AIF↑, 4,   APAF1↑, 6,   Apoptosis?, 3,   Apoptosis↓, 7,   Apoptosis↑, 233,   mt-Apoptosis↑, 1,   ASC↓, 1,   ASC↑, 1,   ASK1↑, 1,   BAD↓, 1,   BAD↑, 3,   Bak↑, 2,   BAX↓, 1,   BAX↑, 84,   Bax:Bcl2↑, 14,   Bcl-2↓, 99,   Bcl-xL↓, 15,   BIM↑, 2,   BNIP3↑, 1,   Casp↑, 24,   Casp1↓, 1,   Casp1↑, 1,   cl‑Casp1↑, 1,   proCasp1↓, 1,   Casp10↓, 1,   Casp10∅, 1,   Casp12↑, 1,   cl‑Casp12↑, 1,   Casp2↑, 1,   Casp3↓, 2,   Casp3↑, 94,   cl‑Casp3↑, 24,   Casp7↑, 13,   cl‑Casp7↑, 1,   Casp8↓, 1,   Casp8↑, 23,   Casp8∅, 1,   cl‑Casp8↑, 3,   proCasp8↑, 1,   Casp9↓, 1,   Casp9↑, 58,   p‑Casp9↑, 1,   cl‑Casp9↑, 8,   cFLIP↓, 2,   Cupro↑, 1,   Cyt‑c↓, 2,   Cyt‑c↑, 47,   Cyt‑c↝, 1,   DR5↑, 10,   DR5∅, 1,   Endon↑, 1,   FADD↑, 3,   FADD∅, 1,   Fas↓, 2,   Fas↑, 11,   FasL↓, 1,   FasL↑, 4,   Ferroptosis↑, 22,   GSDMD↑, 2,   IAP1↓, 5,   IAP2/BIRC3↓, 2,   cl‑IAP2/BIRC3↑, 1,   iNOS↓, 7,   Mcl-1↓, 10,   Mcl-1↑, 1,   MDM2↓, 7,   MDM2↑, 1,   MOMP↓, 1,   MOMP↑, 3,   Necroptosis↑, 2,   necrosis↑, 2,   NOXA↑, 2,   P2X7↓, 1,   p38↓, 6,   p38↑, 9,   p‑p38↓, 4,   p‑p38↑, 3,   p‑p38↝, 1,   Paraptosis↑, 1,   PDCD4↑, 1,   PUMA↑, 2,   Pyro↑, 3,   RIP1↓, 1,   survivin↓, 38,   TNFR 1↓, 1,   TRAILR↑, 1,   TumCD↓, 1,   TumCD↑, 9,   TUNEL↑, 1,   XIAP↓, 19,   YAP/TEAD↓, 6,   YAP/TEAD↑, 1,   β-TRCP↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

ABL1↓, 1,   Akt↓, 122,   Akt↑, 5,   Akt↝, 1,   p‑Akt↓, 43,   p‑Akt↑, 1,   AKT1↓, 4,   AKT3↓, 1,   p‑CaMKII ↓, 1,   CIP2A↓, 1,   CK2↓, 4,   cMET↓, 1,   p‑cMET↑, 2,   cSrc↓, 1,   EF-1α↓, 1,   EGFR↓, 34,   p‑EGFR↓, 1,   ERK↓, 31,   ERK↑, 7,   ERK↝, 2,   p‑ERK↓, 17,   p‑ERK↑, 1,   p‑ERK↝, 1,   FGFR1↓, 1,   HER2/EBBR2↓, 10,   p‑HER2/EBBR2↓, 1,   IGF-1R↓, 2,   IGFR↓, 1,   p‑IGFR↓, 1,   IKKα↓, 10,   IKKα↝, 1,   p‑IKKα↓, 1,   IR↓, 1,   IκB↑, 1,   p‑IκB↓, 1,   p‑IκB↑, 1,   JAK↓, 6,   JAK↝, 1,   p‑JAK↓, 1,   JAK1↓, 2,   JAK2↓, 11,   p‑JAK2↓, 2,   p‑JAK3↓, 1,   JNK↓, 3,   JNK↑, 10,   JNK↝, 1,   p‑JNK↓, 2,   p‑JNK↑, 1,   p‑JNK↝, 1,   p‑MAP2K1/MEK1↓, 1,   MAPK↓, 27,   MAPK↑, 9,   MAPK↝, 1,   p‑MAPK↓, 2,   p‑MAPK↑, 1,   MEK↓, 4,   p‑MEK↓, 2,   mTOR↓, 66,   mTOR↑, 4,   mTOR↝, 1,   p‑mTOR↓, 12,   mTORC2↓, 2,   mTORC2↑, 1,   NRAS↓, 1,   p42↑, 1,   P70S6K↓, 4,   p‑P70S6K↓, 1,   P90RSK↓, 1,   p‑P90RSK↑, 1,   p‑PDGFR-BB↓, 1,   PDGFRA↓, 1,   PFKFB2↓, 1,   PI3K↓, 82,   PI3K↝, 1,   p‑PI3K↓, 13,   PI3K/Akt↓, 4,   PI3k/Akt/mTOR↓, 1,   PIK3CA↓, 1,   PKA↓, 1,   PKCδ↓, 8,   p‑PKCδ↓, 1,   PP2A↑, 1,   PRAS40↑, 1,   PTEN↑, 22,   PTK2B / PYK2↓, 1,   Raf↓, 3,   c-Raf↓, 1,   RAS↓, 10,   RAS↑, 1,   p‑S6K↓, 1,   SGK1↓, 1,   Sp1/3/4↓, 19,   Src↓, 4,   p‑Src↓, 1,   STAT↓, 6,   p‑STAT↓, 1,   p‑STAT2↓, 1,   STAT3↓, 57,   STAT3↑, 3,   p‑STAT3↓, 10,   p‑STAT3↑, 2,   STAT5↓, 1,   STAT6↓, 3,   THEM4/CTMP↑, 1,   TSC2↑, 2,   p‑TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF3↑, 2,   ATF4↑, 6,   ATF4↝, 1,   CBP↓, 2,   cJun↓, 6,   cJun↑, 2,   p‑cJun↓, 1,   cMyc↓, 26,   DNMT1↓, 4,   DNMT1↑, 1,   DNMTs↓, 2,   EZH2↓, 1,   FOXM1↓, 2,   FOXO↑, 2,   FOXO1↓, 2,   FOXO1↑, 1,   FOXO3↑, 4,   p‑FOXO3↓, 1,   FOXO4↓, 1,   FOXO4↑, 1,   H3↑, 1,   ac‑H3↑, 2,   H4↑, 2,   ac‑H4↑, 1,   HATs↓, 5,   HATs↑, 1,   HDAC↓, 11,   HDAC1↓, 4,   HDAC3↓, 1,   HDAC4↓, 1,   HDAC6↓, 2,   HDAC8↓, 1,   HES1↓, 2,   HMTs↓, 1,   HOXB-AS1↓, 1,   JPT1/HN1↓, 1,   KISS1↑, 1,   LINC01116↓, 1,   Matr↓, 1,   METTL7A↑, 1,   miR-107↑, 2,   miR-10b-5p↓, 1,   miR-124-3p↓, 1,   miR-130a↓, 2,   miR-133a-3p↑, 1,   miR-139-5p↑, 3,   miR-145↑, 1,   miR-149↑, 1,   miR-155↓, 2,   miR-182-5p↓, 1,   miR-192-5p↑, 1,   miR-194↑, 1,   miR-200b↑, 1,   miR-205↑, 2,   miR-206↑, 1,   miR-21↓, 8,   miR-223-3p↓, 1,   miR-224↓, 2,   miR-25-5p↓, 1,   miR-29b↑, 1,   miR-301a-3p↓, 1,   miR-30a-5p↑, 1,   miR-340↓, 2,   miR-34a↓, 1,   miR-34a↑, 5,   miR-375↑, 2,   miR-384↑, 1,   miR-422a↑, 2,   miR-542↓, 1,   miR-590-3p↑, 1,   miR-592↑, 1,   miR-7641↓, 1,   miR-99↑, 1,   Myc↓, 1,   Myc↑, 1,   NDRG1↑, 1,   OCT4↓, 12,   other?, 1,   other↓, 2,   other↑, 3,   other↝, 11,   PCAF↓, 1,   PhotoS↑, 2,   RASSF1A↑, 1,   sonoS↑, 1,   SOX2↓, 10,   SOX4↓, 1,   SOX4↑, 1,   SUV39H↓, 1,   TCF-4↓, 1,   TLE1↓, 1,   tumCV↓, 71,   tumCV∅, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 18,   cl‑CHOP/DDIT3↑, 1,   CUL1↝, 1,   CUL5↝, 1,   eIF2α↓, 1,   eIF2α↑, 4,   p‑eIF2α↑, 2,   ER Stress↑, 27,   Erlin1↑, 1,   GRP78/BiP?, 1,   GRP78/BiP↓, 2,   GRP78/BiP↑, 8,   HSP70/HSPA5↓, 3,   HSP70/HSPA5↑, 1,   e-HSP70/HSPA5↓, 1,   HSP90↓, 13,   HSPs↓, 1,   IRE1↑, 3,   OTUB2↓, 1,   PDI↑, 1,   PERK↑, 9,   p‑PERK↑, 1,   Proteasome↓, 1,   UPR↓, 1,   UPR↑, 2,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG13↑, 1,   ATG16L1↑, 1,   ATG3↑, 1,   ATG5↓, 1,   ATG5↑, 2,   ATG7↑, 2,   Beclin-1/ATG6↓, 4,   Beclin-1/ATG6↑, 5,   LC3‑Ⅱ/LC3‑Ⅰ↑, 3,   LC3A↑, 2,   LC3B↑, 1,   LC3B-II↓, 1,   LC3B-II↑, 1,   LC3I↑, 1,   LC3II↓, 1,   LC3II↑, 7,   LC3s↑, 1,   MitoP↑, 1,   p62↓, 4,   p62↑, 3,   p‑p62↑, 1,   PARK2↑, 3,   RUBCN↓, 1,   SESN2↑, 1,   TumAuto↓, 1,   TumAuto↑, 42,   TumAuto⇅, 1,   TumAuto↝, 1,   ULK1/ATG1↑, 1,   VMP-1↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 3,   BRCA1↓, 2,   BRCA1↑, 2,   BRCA2↑, 1,   DNAdam↓, 1,   DNAdam↑, 33,   DNArepair↓, 5,   ERCC1↓, 2,   ERCC3↑, 1,   ERCC4/XPF↓, 1,   m-FAM72A↓, 1,   hTERT/TERT↓, 3,   Ku70/XRCC6↓, 1,   p16↑, 2,   P53?, 1,   P53↓, 1,   P53↑, 50,   p‑P53↑, 3,   p73↑, 1,   PARP↓, 3,   PARP↑, 9,   cl‑PARP↑, 42,   PARP1↑, 1,   cl‑PARP1↑, 1,   PCNA↓, 21,   PCNA↑, 1,   POLD1↓, 1,   Telomerase↓, 5,   TOP1↓, 3,   TOP2↓, 2,   TOP2↑, 1,   TP53↑, 2,   XRCC1↓, 1,   γH2AX↑, 5,   γH2AX↝, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CC(CDKs/cyclins)↓, 2,   CDK1↓, 9,   CDK1↑, 1,   CDK2↓, 20,   CDK2↑, 3,   CDK4↓, 25,   CDK4↑, 2,   CDK4∅, 1,   CDK4/6↓, 1,   CDK6↓, 10,   CDK6↑, 2,   CDK6∅, 1,   CDK7↓, 1,   cellSen↑, 1,   CHK1↓, 1,   CHK1↑, 1,   p‑CHK1↑, 1,   Chk2↑, 1,   p‑Chk2↑, 1,   Cyc↓, 1,   cycA1/CCNA1↓, 7,   CycB/CCNB1↓, 15,   cycD1/CCND1↓, 53,   cycD1/CCND1↑, 2,   cycD1/CCND1∅, 1,   CycD3↓, 3,   cycE/CCNE↓, 14,   E2Fs↓, 2,   Ki-67↓, 31,   MAD↓, 1,   P21?, 1,   P21↓, 3,   P21↑, 40,   p27/CDKN1B↓, 2,   p27/CDKN1B↑, 10,   p‑pRB↓, 2,   RB1↓, 1,   RB1↑, 1,   p‑RB1↓, 3,   RRM2↓, 1,   Securin↓, 1,   TumCCA↓, 6,   TumCCA↑, 149,   WEE1↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 2,   p‑4E-BP1↓, 2,   ALDH↓, 8,   ALDH1A1↓, 1,   Axin2↑, 1,   BMI1↓, 1,   BMP2↓, 1,   BMPs↑, 2,   CD133↓, 11,   CD133↑, 1,   CD24↓, 4,   CD34↓, 1,   cFos↓, 7,   p‑cFos↓, 1,   cMYB↓, 1,   CSCs↓, 38,   Diff↑, 5,   FGF↓, 2,   FGF↑, 1,   Gli↓, 1,   Gli1↓, 13,   HH?, 1,   HH↓, 12,   IGF-1↓, 4,   IGFBP3↓, 1,   IGFBP3↑, 2,   JAG1↓, 1,   Jun↓, 2,   Ki-67↓, 31,   Let-7↑, 1,   LRP6↓, 2,   p‑LRP6↓, 2,   MCM2↓, 1,   mTORC1↓, 5,   Nanog↓, 10,   Nestin↓, 3,   NOTCH↓, 10,   NOTCH↑, 1,   NOTCH1↓, 5,   NOTCH1↝, 1,   NOTCH3↓, 3,   OGFr↑, 2,   p300↓, 3,   PCLAF↓, 1,   Piezo1↑, 2,   PTCH1↓, 3,   PTCH2↓, 1,   SCF↓, 1,   Shh↓, 4,   Smo↓, 6,   STAT1↓, 1,   p‑STAT1↓, 1,   Sufu↓, 1,   TAZ↓, 1,   TOPflash↓, 2,   TumCG?, 2,   TumCG↓, 108,   TumCG↑, 3,   TumCG∅, 1,   TumCP?, 1,   TumCP↓, 240,   TumCP↑, 5,   tyrosinase↓, 1,   URGCP/URG4↓, 1,   WDR72↓, 1,   Wnt↓, 30,   Wnt/(β-catenin)↓, 7,   ZFX↓, 1,  

Migration(tgid=13) ⓘ

AGRN↓, 1,   annexin II↓, 1,   AntiAg?, 1,   AntiAg↑, 3,   AP-1↓, 10,   AP-1↝, 1,   ASAP2↓, 1,   Ca+2↑, 20,   CAFs/TAFs↓, 1,   CAFs/TAFs↝, 1,   cal2↑, 2,   Cav1↓, 1,   p‑Cofilin↑, 2,   COL11A1↓, 1,   E-cadherin↓, 6,   E-cadherin↑, 70,   EMT?, 1,   EMT↓, 124,   EMT↑, 4,   EpCAM↓, 3,   F-actin↓, 3,   FAK↓, 14,   FAK↑, 1,   p‑FAK↓, 3,   Fibronectin↓, 7,   GLI2↓, 2,   ITGA2↓, 1,   ITGA5↓, 1,   ITGA6↓, 1,   ITGB1↓, 4,   ITGB3↓, 1,   ITGB4↓, 3,   ITGB6↓, 1,   LAMs↓, 1,   LEF1↓, 2,   LRP1↓, 1,   MALAT1↓, 3,   MET↓, 2,   MET↑, 1,   p‑MET↓, 1,   MMP-10↓, 1,   MMP1↓, 5,   MMP13↓, 5,   MMP14↓, 2,   MMP16↓, 2,   MMP17↓, 1,   MMP2?, 1,   MMP2↓, 117,   MMP2↝, 1,   MMP3↓, 8,   MMP7↓, 11,   MMP9?, 1,   MMP9↓, 133,   MMP9↑, 1,   MMP9↝, 1,   MMPs↓, 32,   MTA1↓, 2,   MUC1↓, 1,   MUC4↓, 1,   N-cadherin?, 1,   N-cadherin↓, 53,   NEDD9↓, 3,   p44↑, 1,   PAK1↓, 1,   pax↓, 1,   PDGF↓, 4,   RECK↑, 2,   RHBDD1↓, 1,   Rho↓, 5,   ROCK1↓, 7,   Sharpin↓, 1,   Slug↓, 27,   Smad1↓, 2,   Smad1↑, 1,   Smad1↝, 1,   SMAD2↓, 4,   p‑SMAD2↓, 9,   SMAD3↓, 8,   p‑SMAD3↓, 7,   SMAD4↓, 1,   p‑SMAD4↓, 1,   Snail↓, 44,   Snail↑, 1,   T-cadherin↑, 1,   talin?, 1,   talin↓, 1,   TET1↓, 1,   TET1↑, 3,   TGF-β↓, 17,   TGF-β↑, 3,   TGF-β↝, 1,   TGF-β1↓, 3,   THBS1↓, 1,   TIMP1↓, 1,   TIMP1↑, 7,   TIMP2↓, 2,   TIMP2↑, 9,   TIMP3↑, 2,   TRIB3↑, 1,   TSC1↑, 1,   TSP-1↑, 1,   TumCA↓, 10,   TumCA↑, 1,   TumCI?, 1,   TumCI↓, 541,   TumCI↑, 7,   TumCMig?, 1,   TumCMig↓, 344,   TumCMig↑, 5,   TumMeta↓, 118,   TumMeta↑, 5,   Twist↓, 16,   Twist↑, 1,   TXNIP↑, 1,   uPA↓, 14,   uPAR↓, 2,   UroPA↓, 1,   Vim?, 1,   Vim↓, 58,   Vim↑, 1,   vinculin↓, 1,   Zeb1↓, 17,   Zeb1↑, 1,   ZEB2↓, 3,   ZEB2↑, 1,   α-SMA↓, 3,   α-SMA↑, 1,   α-tubulin↑, 2,   β-catenin/ZEB1↓, 53,   β-catenin/ZEB1↑, 2,   cl‑β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 96,   angioG↑, 2,   EGR1↓, 1,   EGR4↓, 1,   eNOS↓, 1,   HIF-1↓, 6,   Hif1a↓, 52,   Hif1a↑, 1,   Hif1a↝, 1,   NO↓, 1,   PHDs↑, 1,   TXA2↓, 1,   VEGF↓, 69,   VEGF↑, 1,   VEGFR1↓, 2,   VEGFR2/KDR/Flk1↓, 8,  

Barriers & Transport(tgid=15) ⓘ

AQPs↓, 1,   BBB↑, 2,   CLDN1↓, 1,   CLDN1↑, 1,   CX43/GJA1↓, 1,   EPR↑, 2,   GLUT1↓, 12,   GLUT1∅, 1,   GLUT3↓, 1,   GLUT3∅, 1,   MMP↓, 65,   MMP↑, 1,   MPT↑, 4,   OATPs↓, 1,   TRPM7↓, 2,   TRPM7↑, 1,   TRPV1↑, 1,   ZO-1↓, 1,   ZO-1↑, 4,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CB2 / CNR2↑, 1,   CD25+↑, 1,   CD4+↓, 1,   CD4+↑, 2,   CD44↓, 13,   CD47↓, 1,   CD8+↑, 5,   p‑cDC2↓, 1,   COX1↓, 3,   COX2/PTGS2↓, 37,   COX2/PTGS2↑, 2,   COX2/PTGS2↝, 1,   CXCL12↓, 2,   CXCR2↓, 1,   CXCR4↓, 11,   DR4↑, 7,   DR4∅, 1,   FOXP3↑, 1,   Gal-3↓, 2,   HLA-I/II↑, 1,   HMGB1↓, 2,   ICAM-1↓, 4,   IFN-γ↑, 1,   Igs↑, 1,   IL1↓, 3,   IL10↓, 1,   IL12↓, 1,   IL12↑, 1,   IL18↓, 2,   IL1α↓, 2,   IL1β↓, 11,   IL2↓, 2,   IL6↓, 26,   IL6↑, 1,   IL8↓, 8,   Imm↑, 11,   Imm↝, 2,   Inflam↓, 34,   Inflam↝, 2,   IRAK4↓, 1,   LIF↑, 1,   LRIG1↑, 1,   M2 MC↓, 1,   MCP1/CCL2↓, 5,   MCT1↓, 1,   MIP2↓, 1,   NF-kB↓, 114,   NF-kB↑, 6,   NF-kB↝, 2,   p‑NF-kB↓, 4,   p‑NF-kB↑, 1,   NFKBIZ/IκBζ↓, 1,   NK cell↑, 3,   NLRP3↓, 5,   NLRP3↑, 2,   p65↓, 5,   p‑p65↓, 2,   PD-1↓, 3,   PD-L1↓, 8,   PD-L1↑, 2,   PGE2↓, 12,   PSA↓, 2,   T-Cell↑, 1,   TCF↓, 2,   Th1 response↑, 1,   TLR2↓, 1,   TLR4↓, 8,   TNF-α↓, 20,   TNF-α↑, 3,   TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, 1,   WFDC10A↑, 1,  

Cellular Microenvironment(tgid=17) ⓘ

GGT/CD224↓, 1,   pH↑, 1,   e-pH↑, 3,   i-pH↓, 1,   TAMS↓, 1,   TAMS↝, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 1,   PTN↓, 1,  

Protein Aggregation(tgid=19) ⓘ

BACE/β-secretase↓, 1,   XO↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AhR↓, 1,   AhR↑, 2,   AhR↓, 1,   AR↓, 10,   ER-α36↓, 2,   ERα/ESR1↓, 1,   Estro↝, 1,   EstroRS/ERS↑, 1,   FGF21↓, 1,   NR3C2/MR↑, 2,   PPARα↓, 1,   PPARα↑, 1,   PPARα↝, 1,   PPARγ↑, 5,   RANKL↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 3,   AKR1B10↓, 1,   BioAv↓, 22,   BioAv↑, 23,   BioAv↝, 11,   BioEnh?, 1,   BioEnh↑, 2,   ChemoSen↓, 2,   ChemoSen↑, 107,   CompStab↓, 1,   CYP1A1↓, 1,   CYP1A1↑, 1,   CYP1A2↑, 1,   CYP2A3/CYP2A6↓, 1,   CYP2E1↑, 1,   CYP3A4↓, 2,   DDS↑, 1,   Dose↓, 5,   Dose↑, 3,   Dose↝, 42,   Dose∅, 4,   eff↓, 20,   eff↑, 55,   eff↝, 3,   eff∅, 1,   GSTZ1↓, 1,   Half-Life↓, 7,   Half-Life↑, 2,   Half-Life↝, 7,   MDR1↓, 2,   MRP1/ABCC1↓, 2,   NAT↓, 1,   P-gp/ABCB1↓, 14,   P450↓, 1,   RadioS?, 1,   RadioS↑, 31,   selectivity↑, 62,   Synergy↑, 75,  

Clinical Biomarkers(tgid=22) ⓘ

AFP?, 1,   AFP↓, 1,   ALAT↓, 2,   ALB↑, 1,   ALP↓, 2,   AR↓, 10,   ascitic↓, 1,   AST?, 1,   AST↓, 1,   BMD↑, 2,   BP↓, 1,   BRCA1↓, 2,   BRCA1↑, 2,   CRP↓, 1,   DBIL↓, 1,   EGFR↓, 34,   p‑EGFR↓, 1,   ERα/ESR1↓, 1,   EstroRS/ERS↑, 1,   EZH2↓, 1,   Ferritin↓, 1,   FOXM1↓, 2,   HER2/EBBR2↓, 10,   p‑HER2/EBBR2↓, 1,   hTERT/TERT↓, 3,   IBIL↓, 1,   IL6↓, 26,   IL6↑, 1,   LDH↓, 7,   LDH↑, 2,   Myc↓, 1,   Myc↑, 1,   NOS2↓, 1,   PD-L1↓, 8,   PD-L1↑, 2,   PSA↓, 2,   TBIL↓, 1,   TG/TAG↓, 1,   TP53↑, 2,   TRIB3↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   AntiCan↑, 32,   AntiCan⇅, 1,   AntiCan∅, 1,   antiD↑, 1,   AntiDiabetic↑, 2,   antiNeop↑, 3,   AntiTum↓, 3,   AntiTum↑, 23,   cachexia↓, 1,   cardioP↑, 6,   CardioT↑, 1,   chemoP?, 1,   chemoP↑, 18,   chemoPv↑, 15,   ChemoSideEff↓, 3,   fatigue↓, 2,   FTO↓, 1,   FTO↑, 1,   hepatoP↓, 1,   hepatoP↑, 4,   Mucositis↓, 1,   neuroP↑, 4,   NP/CIPN↓, 1,   OS↑, 11,   Pain↓, 1,   PFS↑, 1,   Pin1↓, 1,   QoL↑, 5,   radioP↑, 6,   Remission↑, 1,   RenoP↑, 2,   Risk↓, 8,   Risk↑, 1,   Sleep↑, 1,   Strength↑, 1,   Symptoms↓, 1,   toxicity?, 1,   toxicity↓, 19,   toxicity↑, 4,   toxicity↝, 5,   toxicity∅, 1,   TumVol↓, 25,   TumVol∅, 1,   TumW↓, 14,   TumW∅, 1,   Weight∅, 1,   Wound Healing↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↓, 1,   GutMicro↑, 3,   Sepsis↓, 2,  
Total Targets: 1048

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 4,   antiOx↑, 50,   Catalase↑, 18,   Fenton↓, 1,   GPx↑, 13,   GPx1↑, 1,   GSH↑, 13,   GSR↑, 1,   GSTs↑, 2,   H2O2↓, 1,   HDL↑, 2,   HO-1?, 1,   HO-1↓, 1,   HO-1↑, 10,   Iron∅, 1,   Keap1↓, 2,   lipid-P↓, 17,   MDA↓, 12,   MPO↓, 2,   NOX↓, 1,   NOX4↓, 1,   NQO1↑, 1,   NRF2↑, 22,   RNS↓, 3,   ROS↓, 44,   ROS↑, 1,   SOD↑, 16,   SOD1↑, 2,   SOD2↑, 1,   TAC↑, 3,   TBARS↓, 1,   VitE↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

compII↑, 1,   compIII↑, 1,   HSP60/HSPD1↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 1,   ALAT↓, 6,   AMPK↓, 1,   AMPK↑, 2,   ATP↓, 1,   ATP↑, 1,   cytoP450↓, 1,   glucose↓, 2,   glucose↑, 1,   glucose↝, 2,   GlucoseCon↑, 2,   HMG-CoA↓, 2,   LDL↓, 3,   NAD↓, 1,   NADPH↓, 2,   NADPH↑, 1,   SIRT1↑, 2,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 3,   BAX↓, 3,   Bcl-2↓, 1,   Bcl-2↑, 1,   Bcl-xL↑, 1,   Casp12↓, 1,   Casp3↓, 5,   Casp9↓, 3,   Cyt‑c↓, 1,   Fas↓, 1,   GranB/GZMB↓, 1,   iNOS↓, 8,   iNOS↑, 1,   p38↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 1,   Akt↑, 4,   p‑Akt↑, 1,   ERK↓, 1,   p‑ERK↑, 1,   HGF/c-Met↑, 1,   IKKα↑, 1,   JAK2↑, 1,   JNK↑, 2,   p‑JNK↓, 1,   MAPK↓, 4,   MAPK↑, 2,   mTOR↓, 2,   mTOR↑, 2,   PI3K↑, 4,   PKCδ↓, 1,   PKCδ↑, 1,   STAT3↑, 2,   p‑STAT3↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 2,   ATF4↓, 2,   cMyc↓, 1,   HDAC↓, 1,   HOTAIR↑, 1,   other↓, 2,   other↑, 1,   other↝, 4,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 2,   CHOP/DDIT3↑, 1,   p‑eIF2α↓, 1,   ER Stress↓, 2,   GRP78/BiP↓, 1,   GRP78/BiP↑, 1,   GRP94↑, 1,   XBP-1↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↓, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3II↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,   P53↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   GADD34↓, 1,   P21↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Diff↝, 1,   TumCP↓, 3,  

Migration(tgid=13) ⓘ

AntiAg↑, 2,   Ca+2↝, 1,   EMT↑, 1,   MMP9↓, 1,   PAI-1/SERPINE1↓, 1,   p‑Rac1↓, 1,   TGF-β↓, 1,   TGF-β↑, 1,   TumCI↓, 2,   TumCI∅, 1,   TumCMig↓, 1,   TumCMig∅, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   E-sel↓, 1,   Hif1a↓, 1,   NO↓, 5,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 3,   GastroP↑, 2,   GLUT2↑, 2,   GLUT3↑, 1,   GLUT4↑, 1,   IBI↑, 3,   MMP↑, 2,   MUC5AC↓, 1,   VGSC↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CCL11↓, 1,   CD25+↑, 1,   CD4+↑, 2,   COX2/PTGS2↓, 12,   FOXP3↑, 1,   HMGB1↓, 1,   IFN-γ↓, 2,   IL1↓, 2,   IL10↓, 3,   IL10↑, 3,   IL12↓, 2,   IL17↓, 1,   IL1β↓, 7,   IL4↓, 1,   IL4↑, 1,   IL6↓, 14,   Imm↓, 1,   Imm↑, 4,   Inflam?, 1,   Inflam↓, 56,   Inflam↑, 2,   IRF3↓, 1,   LPS↓, 1,   M2 MC↑, 1,   MCP1/CCL2↓, 1,   MyD88↓, 1,   NF-kB↓, 13,   NLRP3↓, 3,   PGE2↓, 5,   TLR2↓, 2,   TLR4↓, 4,   TNF-α↓, 14,   Treg lymp↝, 1,   TRIF↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 1,   Ach↑, 1,   AChE↓, 5,   AChE↑, 1,   BChE↓, 1,   BDNF↓, 1,   BDNF↑, 2,   proBDNF↑, 1,   ChAT↑, 1,   MAOA↓, 1,   NGF↑, 1,   TPH1↓, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 2,   APP↓, 1,   Aβ↓, 4,   BACE/β-secretase↓, 1,   tau↓, 1,   p‑tau↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

PPARγ↓, 1,   PPARγ↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 13,   BioAv↑, 20,   BioAv⇅, 1,   BioAv↝, 9,   BioEnh↑, 1,   CompStab↑, 1,   CompStab↝, 1,   Dose↓, 1,   Dose↑, 1,   Dose↝, 7,   eff↑, 5,   Half-Life↓, 3,   Half-Life↝, 2,   Half-Life∅, 1,   P-gp/ABCB1↓, 1,   Synergy↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 6,   ALP↓, 2,   AST↓, 6,   BMD↑, 2,   BP↓, 1,   BUN↓, 1,   creat↓, 1,   CRP↓, 3,   IL6↓, 14,   LDH↓, 2,   SpO2↑, 1,   TG/TAG↓, 1,   Urea↓, 1,  

Functional Outcomes(tgid=23) ⓘ

Analgesic↑, 1,   AntiAge↑, 1,   antiAll↑, 7,   AntiArt↑, 3,   AntiCan↑, 6,   antiD↓, 1,   antiD↑, 1,   AntiDiabetic↑, 8,   antiPs↑, 1,   AntiTum↓, 1,   AntiTum↑, 3,   ANXi↓, 1,   cardioP↑, 19,   chemoP↑, 1,   chemoPv↑, 2,   cognitive↑, 5,   diuretic↑, 1,   hepatoP↑, 17,   memory↑, 3,   Mood↑, 1,   neuroP?, 1,   neuroP↑, 33,   Obesity↓, 3,   OS↑, 1,   Pain↓, 2,   radioP↑, 3,   RenoP↑, 6,   Risk↓, 1,   Sleep↑, 1,   Stroke↓, 3,   toxicity↓, 23,   toxicity↑, 2,   toxicity↝, 6,   toxicity∅, 7,   Weight↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↑, 5,   AntiFungal↑, 1,   AntiP↑, 2,   AntiViral↑, 6,   Bacteria↓, 10,   GutMicro↑, 10,   Sepsis↓, 2,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 2,  
Total Targets: 265

Scientific Paper Hit Count for: TumCI, Tumor Cell invasion
21 Curcumin
15 Resveratrol
14 Quercetin
13 Matrine
12 Honokiol
12 Magnolol
12 Shikonin
11 Berberine
11 Fisetin
10 Apigenin (mainly Parsley)
10 EGCG (Epigallocatechin Gallate)
10 Sulforaphane (mainly Broccoli)
9 Thymoquinone
8 Melatonin
8 Eugenol
8 Garcinol
8 Luteolin
7 Ashwagandha(Withaferin A)
7 Betulinic acid
7 Chlorogenic acid
7 Chrysin
7 Licochalcone A
7 Magnetic Fields
6 Metformin
6 Cinnamon
6 Dandelion Root
6 Emodin
6 Formononetin
6 Ginkgetin
6 Piperlongumine
5 Astragalus
5 Gemcitabine (Gemzar)
5 Ferulic acid
5 Hyperoside
5 Lycopene
5 Morin
5 Pterostilbene
4 Artemisinin
4 Baicalein
4 Carvacrol
4 Celastrol
4 Cyclopamine
4 Radiotherapy/Radiation
4 Gambogic Acid
4 Isoliquiritigenin
4 Juglone
4 Nimbolide
4 Phenethyl isothiocyanate
4 Rosmarinic acid
4 Silymarin (Milk Thistle) silibinin
4 Urolithin
3 Silver-NanoParticles
3 Alpha-Lipoic-Acid
3 Berbamine
3 Brucea javanica
3 brusatol
3 Capsaicin
3 NTP, Non-Thermal Plasma,Cold Atmospheric Plasma
3 Centella asiatica / Gotu kola → asiaticoside
3 chaetocin
3 Zinc
3 Propolis -bee glue
3 Crocetin
3 Copper and Cu NanoParticles
3 Diindolylmethane
3 Evodiamine
3 Gallic acid
3 Paclitaxel/Taxol
3 Genistein (soy isoflavone)
3 Hydrogen Gas
3 Indole-3-carbinol
3 iodine
3 Magnetic Field Rotating
3 Bicarbonate(Sodium)
3 Piperine
3 Whole Body Vibration
2 alpha Linolenic acid
2 Phyllanthus emblica/Emblica officinalis/Amla / Indian Gooseberry
2 Aspirin
2 Astaxanthin
2 Beta-Caryophyllene
2 Boron
2 Boswellia (frankincense)
2 α-Bisabolol / Chamomile oil
2 Caffeic Acid Phenethyl Ester (CAPE)
2 Celecoxib
2 Hydroxycinnamic-acid
2 Cynara scolymus/Globe Artichoke/Artichoke Extract
2 Dasatinib/Phyrago
2 Deguelin
2 Disulfiram
2 Ellagic acid
2 Ginkgolic acids
2 Ginkgolide B
2 5-fluorouracil
2 Graviola
2 Grapeseed extract
2 Hibiscus sabdariffa
2 HydroxyTyrosol
2 isoflavones
2 isoorientin
2 isoquercitrin
2 itraconazole
2 Kaempferol
2 low dose naltrexone
2 Licorice
2 Linalool
2 Lutein
2 Modified Citrus Pectin
2 Mushroom Chaga, Inonotus obliquus
2 Marjoram (Origanum majorana)
2 Cisplatin
2 salinomycin
2 Sulfasalazine
2 Selenite (Sodium)
2 Aflavin-3,3′-digallate
2 Vitamin C (Ascorbic Acid)
1 1,8-Cineole
1 3-bromopyruvate
1 Ajoene (compound of Garlic)
1 DTS(dibenzyl trisulphide) from Anamu
1 Andrographis
1 Ascorbyl Palmitate
1 Aloe anthraquinones
1 Biochanin A
1 Atorvastatin
1 bempedoic acid
1 Bufalin/Huachansu
1 Bacopa monnieri
1 Butyrate
1 Carnosic acid
1 chitosan
1 Selenium NanoParticles
1 Chlorophyllin
1 Carvone
1 CUSP9
1 Cynaropicrin
1 Cysteamine
1 Dichloroacetate
1 Date Fruit Extract
1 Mistletoe/Viscum album Extracts
1 Ginkgo biloba-EGb 761
1 eicosapentaenoic acid
1 Sorafenib (brand name Nexavar)
1 Fucoidan
1 Galloflavin
1 Ginkgo biloba
1 Geraniol
1 Ginseng
1 γ-linolenic acid (Borage Oil)
1 Gossypol/AT-101
1 Proanthocyanidins
1 Hops (Humulus lupulus)
1 Isobavachalcone
1 phytic acid, Inositol hexakisphosphate
1 Ivermectin
1 Isovitexin
1 Lactoferrin/Talactoferrin
1 SDG/lignans
1 mebendazole
1 Methyl Jasmonate
1 methylseleninic acid
1 Methyl salicylate / Sweet Birch oil
1 doxorubicin
1 immunotherapy
1 Magnesium
1 Methylsulfonylmethane
1 Mushroom Lion’s Mane, Hericium erinaceus
1 Noscapine
1 Oroxylin A
1 Oleuropein
1 Orlistat
1 Psoralidin
1 Docetaxel
1 Germacranolide sesquiterpene lactone
1 Rauwolfia serpentina/Indian Snakeroot
1 Salvia miltiorrhiza
1 Terpinen-4-ol / Tea Tree Oil
1 Thymol-Thymus vulgaris
1 Ursolic acid
1 Usnic acid
1 Arsenic trioxide
1 Vitamin K2
1 VitK3,menadione
1 Vitexin
1 β‐Elemene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:324  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page